Work

Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment.

Year: 2017

Type: article

Study design: Observational Study

Abstract: patients with high levels of meEGFR-CTCs ratio (≥ 0.23) had significantly inferior PFS with anti-EGFR treatment (HR = 3.4, 95% CI 1.5-7.9, P = 0.004). By contrast, high levels of meEGFR in the untreated tumor tissues had no correlation with anti-EGFR treatment duration in cohort 2. Therefore, meEGFR-CTCs may have the potential to serve as a "liquid biopsy" biomarker to predict anti-EGFR treatment efficacy.

Source: PubMed

Authors: Krittiya Korphaisarn, Chao-Kai Chou, Wei-Ya Xia, Callisia N Clarke, Riham Katkhuda, Jennifer S Davis, Kanwal Ps Raghav, Hsin-Wei Liao, Ji-Yuan Wu, David G Menter, Dipen M Maru, Mien-Chie Hung, Scott Kopetz

Institutions: Siriraj Hospital, The University of Texas MD Anderson Cancer Center, Harvard University, Massachusetts General Hospital, Center for Systems Biology, Asia University, China Medical University

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Award: Cancer Center Support Grant

OpenAlex ID: W2794038133

FWCI: 0.262

Cites: 51

Cited by: 3

Related to: 10